#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Lisa M. Coussens & Zena WelAP5 Rec'd PCT/PTO 08 FEB 2006

**APPLICATION NO.:** 

Not Yet Known

FILING DATE:

February 7, 2006

TITLE:

Novel Indicators for Transforming Growth Factor-Beta Regulators

**EXAMINER:** 

Not Yet Known

**GROUP ART UNIT:** 

Not Yet Known

ATTY. DKT. NO.:

23540-09361

#### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

the date shown below:

Dated: Feb. 8/2006

Bv:

Narinder S. Banait, Reg. No.: 43,482

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS

P.O. BOX 1450

ALEXANDRIA, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT Under 37 CFR §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 CFR §§ 1.56 and 1.97-98, enclosed herewith is modified form PTO/SB/08A listing references for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

This Information Disclosure Statement is being filed:

$\boxtimes$	within three months of the filing date of the application, or date of entry into
	the national stage of an international application, or before the mailing date of
	a first office action on the merits, whichever event last occurred;

before the mailing of a first official action after the filing of a request for
continued examination (RCE) under 37 CFR § 1.114;

### IAP5 Rec'd PCT/PTO 08 FEB 2006 10/567873 PATENT

Ц		after three months of the filing date of this national application or the date of								
	entry of the national stage in an international application, or after the mailing									
		date of the first official action on the merits, whichever event last occurred, but								
		before the mailing date of the first to occur of either: (1) a final action under								
	37 CFR §1.113; or (2) an action that otherwise closes prosecution in the									
	application, and:									
		attached hereto is the fee set forth under 37 CFR §1.17(p) for								
		subm	submission of this Information Disclosure Statement under 37 CFR.§							
		1.97(c); OR								
		Appl	Applicant certifies pursuant to 37 CFR § 1.97(e) that:							
	•		each item of information contained in this Information							
			Disclosure Statement was first cited in a communication from							
			a foreign patent office in a counterpart foreign application not							
			more than three months prior to the filing of this Statement;							
	•		OR							
•			no item of information contained in this Information							
		٠	Disclosure Statement was cited in a communication from a							
			foreign patent office in a counterpart foreign application and,							
			to the knowledge of the person signing this certification after							
			making reasonable inquiry, no item of information contained							
			in this Statement was known to any individual designated							
	•		under 37 CFR § 1.56(c) more than three months prior to the							
			filing of this Statement;							
	on or	on or before the payment of the issue fee but after the mailing date of the first								
	to oc	cur of e	ither: (1) a final action under 37 CFR § 1.113; (2) a notice of							
	allowance under 37 CFR § 1.311; or (3) an action that otherwise closes									
	prose	cution i	n the application, and:							
	Applicant certifies pursuant to 37 CFR. § 1.97(e) that:									
			each item of information contained in this Information							
			Disclosure Statement was cited in a communication from a							
			foreign patent office in a counterpart foreign application not							
			more than three months prior to the filing of this Statement;							
			no item of information contained in this Information							
			Disclosure Statement was cited in a communication from a							
			foreign patent office in a counterpart foreign application and,							
			to the knowledge of the person signing this certification after							
			making reasonable inquiry, no item of information contained							

# IAP5 Rec'd PCT/PTO 08 FEB 2006 10/567873 PATE

in this Statement was known to any individual designated under 37 CFR § 1.56(c) more than three months prior to the filing of this Statement; AND attached hereto is the fee set forth under 37 CFR §1.17(p) for submission of this Information Disclosure Statement under 37 CFR.§ 1.97(d); OR after the payment of the issue fee. Applicant requests that the information contained in this Information Disclosure Statement be placed in the file according to 37 CFR § 1.97(i), although the information may not be considered by the USPTO. Enclosed is a copy of each listed reference that may be material to the examination of this application, and for which there may be a duty to disclose. This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application No. \_\_\_\_\_, filed on \_\_\_\_\_, and the references cited therein are hereby referenced, but are not required to be provided in this application under 37 CFR § Copies of any foreign patent documents and non-patent literature cited herein are Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 CFR § 1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement. 37 CFR § 1.704(d). Applicant submits that no fee is required for the consideration of this Information Disclosure Statement.

Consideration of the listed references and favorable action are solicited.

Respectfully submitted,

LISA M. COUSSENS ET AL.

Dated: <u>Feb.</u> 8/2006

П

1.98(d).

enclosed.

 $\boxtimes$ 

 $\boxtimes$ 

 $\boxtimes$ 

Narinder S. Banait, Reg. No. 43,482

Fenwick & West LLP Silicon Valley Center 801 California Street

Mountain View, CA 94041

Tel.: (650) 335-7818 Fax.: (650) 938-5200

### IAP5 Rec'd PCT/PTO 08 FEB 2006

Substitute for form 1449A/PTO						Complete if Known			
						ication No.	Not Yet Known 10/56	7 <b>97</b>	
INFORMATION DISCLOSURE					Filing Date		February 7, 2006		
STATEMENT BY APPLICANT  Sheet 1 of 1						Named Inventor	Lisa M. Coussens Not Yet Known		
						nit			
						niner Name	Not Yet Known		
						ney Docket Number	23540-09361		
Olicer		1   0,		1	1	,	23340-09301		
			٠						
				U.S.	PATE	NT DOCUMENTS			
	Document No.								
Examiner Initials*	Cite No. <sup>1</sup>			Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document			
		US-	•	<u>-</u>					
		US-							
•	-	١.							
				FOREIC	GN PAT	TENT DOCUMENTS	· · · · · · · · · · · · · · · · · · ·	<u> </u>	
		Foreign Patent Do	cument						
Examiner Initials*	Cite No.1	Country Code <sup>3</sup> – Number <sup>4</sup> Kind Code <sup>5</sup> (if known)		Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		T <sup>6</sup>	
	ļ								
•									
Examiner	Cite					PATENT LITERATU S), title of the article (when	RE DOCUMENTS  appropriate), title of the item (book, magazine,		
Initials*	No. <sup>1</sup>	journal, serial,	symposiu	m, catalog, et	c.), date,	page(s), volume-issue nui published	mber(s), publisher, city and/or country where	T <sup>6</sup>	
	C1	Invitation to pay A	dditional I	Fees and, Wh	ere Appli	cable, Protest Fee, PCT/U	S04/25902, December 14, 2005, 5 pages.		
	C2	LEE, Y.C. et al., "Transforming Growth Factor β Induces Vascular Endothelial Growth Factor Elaboration from Pleural Mesothelial Cells in Vivo and in Vitro," American Journal of Respiratory and Critical Care Medicine, 2002, pp. 88-94, vol. 165.							
	1								
				,					
				<del></del>				<del></del>	
		<del> </del>							
			-					1	
		1				,		1	
	<del> </del>	<b>†</b>			1		in the state of th		
	<del>                                     </del>	<u> </u>						+	

Examiner

Signature

Date

Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.